Change in number of shares and votes in Vitrolife AB (publ)

In accordance with the decision at the board meeting on 8 July 2021, Vitrolife AB has issued a total of 9,645,303 new shares. As of 30 July 2021, following the new issue of shares, the number of shares and votes in Vitrolife AB (publ) amounts to 118,195,878.

Gothenburg, July 30, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on July 30, 2021 at 8.30 am CET.

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/